INVESTOR PRESENTATION
Reverse Cellular Aging at Scale
Patho.ai - Gated Generative AI Therapeutics Platform
Positioning a $50 Million Series A round to accelerate preclinical validation of our primary independent pipelines.
Flagship Asset
Navi Cell (NC-001)
A gated cellular rejuvenation program centered on AP2A1, with confidential workflow data available only under approved access.
Neurology Pipeline
Patho Kappa (PK-104)
Targeted protein degrader addressing key neurodegenerative disease pathways.
Slide 1 of 6